Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q1 FY22 results · Apr–Jun 2021
Tatva Chintan Pharma Chem reported revenue from operations of ₹106.83 crore and net profit of ₹23.15 crore for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 106.83 | — | — | — | — |
| Other income | 2.97 | — | — | — | — |
| Total income | 109.80 | — | — | — | — |
| Profit before tax | 24.26 | — | — | — | — |
| Net profit for the period | 23.15 | — | — | — | — |
| EPS, basic (₹) | 11.52 | — | — | — | — |
| Net margin (%) | 21.7 | — | — |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 107.65 | — | — | — | — |
| Other income | 2.77 | — | — | — | — |
| Total income | 110.42 | — | — | — | — |
| Profit before tax | 24.98 | — | — | — | — |
| Net profit for the period | 23.96 | — | — | — | — |
| EPS, basic (₹) | 11.93 | — | — | — | — |
| Net margin (%) | 22.3 | — | — |
Consolidated
- Filed with BSE
- 17 Aug 2021, 20:16 IST
- Board meeting
- 14 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 Aug 2021, 20:16 IST
- Board meeting
- 14 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE